RCRaif Coşkun

Raif Coşkun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raif Coşkun has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?

    by Güler Yıldırım Nalbant, Raif Coşkun, Nilay Çalışkan, Merve Karaca Şahin, Aslı Berivan Topçak, Muhammed Fatih Erbay, Çağla Öztürk Turan, Hilal Güngör, Hamit Boloğur, Hasan Tunç Şarman, et al.

    Aim: This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods: The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated. Results: In adults, higher baseline Systemic Inflammation Response Index (SIRI) (OR = 0.207, p < 0.001), monocyte count (OR = 0.276, p = 0.002), neutrophil‐to‐lymphocyte ratio (NLR) (OR = 0.455, p = 0.012), and Systemic Immune‐Inflammation Index (SII) (OR = 0.487, p = 0.022) were associated with lower odds of treatment response. In paediatric patients, higher baseline SII was significantly associated with lower odds of response (OR = 0.349, p = 0.040). Interaction analyses showed nominally significant age interactions for baseline SIRI (B = −0.169, p = 0.027) and monocyte count (B = −0.193, p = 0.025). During follow‐up, SIRI was lower in responders from baseline through 12 months in adults, and at 3 and 6 months in children. SII was lower in responders at baseline in adults, and at baseline, 3, and 6 months in children (all p < 0.05). Conclusion: Our findings suggest potential differences in the associations between inflammatory markers and omalizumab response across age groups, though further studies are needed to clarify age‐related differences.

  • Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study

    by Murat Türk, Muhammed Burak Yücel, İnSu Yılmaz, Ragıp Ertaş, Ümit Murat Şahiner, Semra Demir, Aslı Gelincik, Derya Ünal, Şule Çelik Kamacı, Merve Hörmet İğDe, et al.

    Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.

  • Open Access

    Comparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?

    by Osman Ozan Yeğit, Ayşe Feyza Aslan, Raif Coşkun, Pelin Karadağ, İlKim Deniz Toprak, Ali Can, Nida Öztop, Semra Demir, Derya Ünal, Müge Olgaç, et al.


  • Open Access

    Impacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe

    by Müge Olgaç, Osman Ozan Yeğit, Şengül Beyaz, Nida Öztop, Can Tüzer, Deniz Eyice, Pelin Karadağ, Raif Coşkun, Semra Demir, Bahaauddin Çolakoğlu, et al.

  • Open Access

    Impact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment

    by Müge Olgaç, Osman Ozan Yeğit, Şengül Beyaz, Nida Öztop, Can Tüzer, Deniz Eyice, Pelin Karadağ, Raif Coşkun, Semra Demir, Bahaauddin Çolakoğlu, et al.